NYSE American - Delayed Quote USD

Can-Fite BioPharma Ltd. (CANF)

1.9800 +0.0600 (+3.13%)
At close: April 26 at 3:49 PM EDT
1.8300 -0.15 (-7.58%)
After hours: April 26 at 5:37 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for CANF

Recent News: CANF

View More
Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal

Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal
Business Wire 3 days ago
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH

Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
Business Wire 13 days ago
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients

Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
Business Wire 25 days ago

Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV
Newsfile 27 days ago
Can-Fite Reports 2023 Financial Results and Clinical Update

Can-Fite Reports 2023 Financial Results and Clinical Update
Business Wire last month
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference

Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
Business Wire last month
Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada

Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada
Business Wire last month
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication

Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
Business Wire 2 months ago
Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study

Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study
Business Wire 2 months ago
The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies

The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies
Business Wire 4 months ago
Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan

Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan
Business Wire 4 months ago
Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development

Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development
Business Wire 4 months ago
View More

Related Tickers

BLRX BioLineRx Ltd.
0.6116
+6.31%
 
XTLB XTL Biopharmaceuticals Ltd.
2.4220
+0.92%
 
PLUR Pluri Inc.
5.36
+2.23%
 
EVGN Evogene Ltd.
0.6251
-4.91%
 
ENLV Enlivex Therapeutics Ltd.
1.4400
-0.69%
 
ELOX Eloxx Pharmaceuticals, Inc.
0.8058
+2.65%
 
PPBT Purple Biotech Ltd
0.4900
-2.00%
 
SCNI Scinai Immunotherapeutics Ltd.
0.4578
+1.73%
 
ORMP Oramed Pharmaceuticals Inc.
2.4600
+6.96%
 
THAR Tharimmune, Inc.
0.3691
+2.50%